Posted by Michael Wonder on 09 Jan 2020
PHARMAC epilepsy drug process questions
10 January 2020 - There are many unanswered questions about PHARMAC's decision to fund only one brand of the epilepsy drug lamotrigine from last October.
The frustration of those concerned about the impact of the change is understandable.
It has been reported that five people who changed to the new drug have died.
At this point, it cannot be ascertained whether the change in the medication is linked to these deaths.
